The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-A
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma. It is also implicated in the development of other metabolic dysfunction-related diseases. MAFLD has emerged as
| Condition(s) | Non-Alcoholic Fatty Liver Disease |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma. It is also implicated in the development of other metabolic dysfunction-related diseases. MAFLD has emerged as a growing public health concern in China. Despite its potential benefits, Tai Chi exercise has not been widely adopted for individuals with MAFLD, and there is limited research investigating its therapeutic efficacy. This study aims to evaluate the effects of a structured Tai Chi intervention on middle-aged and elderly individuals with MAFLD. Methods: The study employs a comprehensive open, randomized, parallel, and controlled design. Eligible participants will be randomly a |
| Who can participate | Inclusion Criteria: 1. Age between 40 and 75 years; 2. Liver fat content measured by mDixon QUANT is ≥5%; 3. Diagnosis of metabolic associated fatty liver disease; 4. Overweight/obesity (BMI ≥ 24 kg/m²); 5. Signed written informed consent. Exclusion Criteria: 1. Excessive alcohol consumption (definition: in the past 6 months, males have consumed more than 140g of alcohol per week, and females have consumed more than 70g); 2. Fatty liver due to other causes: such as alcoholic fatty liver, acute and chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, etc.; 3. Severe cardiovascular diseases, including myocardial infarction within the past 6 months; 4. Heart failure (NYHA classification: III - IV); 5. Biliary diseases: such as obstructive biliary diseases; 6. Other diseases |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Lead sponsor | Fujian Provincial Hospital |
| Locations | Fuzhou, Fujian, China |
| Start date | 2024-11-01 |
| NCT ID | NCT06717828 |
| Official listing | https://clinicaltrials.gov/study/NCT06717828 |